Dietrich John Pauls insider trades: DiaMedica Therapeutics (DMAC) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Dietrich reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 23, 2023 | DMAC | ↑ Buy | 12,787 | $3.91 | $50K | Direct | Jun 26, 2023 (3d) |
| Nov 16, 2022 | DMAX | ↑ Buy | 20,000 | $1.21 | $24K | Direct | Nov 16, 2022 (0d) |
| Aug 16, 2021 | DMAC | ↑ Buy | 5,000 | $3.14 | $16K | Direct | Aug 16, 2021 (0d) |
| Aug 16, 2019 | DMAC | ↑ Buy | 1,000 | $2.68 | $3K | Direct | Aug 16, 2019 (0d) |
| Dec 11, 2018 | DMAC | ↑ Buy | 5,000 | $4.00 | $20K | Direct | Dec 11, 2018 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DMAC insiders
Open-market trades in the last 12 months
About Dietrich John Pauls's insider trades
Dietrich John Pauls is President & CEO at DiaMedica Therapeutics (DMAC). Since Dec 11, 2018, Dietrich has reported 5 open-market purchases worth $113K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DMAC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.